Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / TRYPF - Tryp Therapeutics discusses unique approach to psychedelic treatment study of binge eating

TRYPF - Tryp Therapeutics discusses unique approach to psychedelic treatment study of binge eating

Tryp Therapeutics Inc Com

--News Direct--

Tryp Therapeutics CEO James Gilligan joins Natalie Stoberman from the Proactive studio to share how the company is developing psychedelic-assisted therapy in treating various disorders such as binge eating and IBS.

Gilligan says Tryp Therapeutics is taking a unique approach with their product, TRP-8803, which is an IV infusion of psilocin, an active metabolite of psilocybin. Currently, Gilligan says the company is using oral psilocybin in their studies while preparing for the use of TRP-8803. Tryp Therapeutics recently secured a $2.4 million private placement that Gilligan says will allow the company to continue their research and upcoming clinical trials.

Contact Details

Proactive Investors

+1 604-688-8158

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/tryp-therapeutics-discusses-unique-approach-to-psychedelic-treatment-study-of-binge-eating-199251568

Stock Information
Company Name: Tryp Therapeutics Inc Com
Stock Symbol: TRYPF
Market: OTC
Website: tryptherapeutics.com
Menu
TRYPF TRYPF Quote TRYPF Short TRYPF News TRYPF Articles TRYPF Message Board
Get TRYPF Alerts

News, Short Squeeze, Breakout and More Instantly...